{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:10:26Z","timestamp":1791259826351,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000960","name":"American College of Rheumatology Research and Education Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008741","name":"European League Against Rheumatism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.semarthrit.2020.09.010","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T18:40:10Z","timestamp":1601404810000},"page":"1314-1325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review"],"prefix":"10.1016","volume":"50","author":[{"given":"Sara","family":"Monti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin A.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Langford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia E.","family":"Lanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Mahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pagnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Bjork","family":"Vi\u00f0arsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Tomasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.semarthrit.2020.09.010_bib0001","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3899\/jrheum.110276","article-title":"The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis","volume":"38","author":"Merkel","year":"2011","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.09.010_bib0002","first-page":"275","article-title":"VITAL (Vasculitis Integrated Assessment Log) assessment of vasculitis","volume":"13","author":"Bacon","year":"1995","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.09.010_bib0003","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.2006.062711","article-title":"EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti\u2010neutrophil cytoplasm antibody\u2010associated vasculitis","volume":"66","author":"Hellmich","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.09.010_bib0004","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.09.010_bib0005","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jclinepi.2013.11.013","article-title":"Developing core outcome measurement sets for clinical trials: OMERACT Filter 2.0","volume":"67","author":"Boers","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.09.010_bib0006","first-page":"671","article-title":"Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis","volume":"87","author":"Luqmani","year":"1994","journal-title":"QJM Mon J Assoc Physicians"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.09.010_bib0007","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0950-3579(97)80052-0","article-title":"Disease assessment and management of the vasculitides","volume":"11","author":"Luqmani","year":"1997","journal-title":"Baillieres Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.09.010_bib0008","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","article-title":"A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.semarthrit.2020.09.010_bib0009","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.010_bib0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00005650-199401000-00004","article-title":"The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups","volume":"32","author":"McHorney","year":"1994","journal-title":"Med Care"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0011","unstructured":"JPRN-JapicCTI-132394. Phase 3 study of GGS in patients with microscopic polyangiitis (MPA). Httpwwwwhointtrialsearchtrial2aspx Trialidjprn-Japiccti-132394 [Internet]. 2019 Mar 31[cited 2019 Jun 8]; Available from:https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01854577\/full"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0012","unstructured":"Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02626845?term=Rituximab+for+the+Otolaryngologic+Manifestations+of+Granulomatosis&rank=1"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.09.010_bib0013","doi-asserted-by":"crossref","first-page":"e16664","DOI":"10.2196\/16664","volume":"9","author":"Merkel","year":"2020","journal-title":"JMIR Res Protoc."},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0014","unstructured":"Alemtuzumab for ANCA Associated Refractory Vasculitis - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 3]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01405807"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0015","unstructured":"Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01446211"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0016","unstructured":"Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03712345"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0017","unstructured":"Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 6]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03895801"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0018","unstructured":"Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 7]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02222155"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.09.010_bib0019","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol JASN"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.09.010_bib0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"QJM Mon J Assoc Physicians"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0021","unstructured":"Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 10]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02108860"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0022","unstructured":"Abatacept in ANCA Associated Vasculitis - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 4]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00482066"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0023","unstructured":"BIANCA-SC: a Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01598857"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.09.010_bib0024","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","article-title":"Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors","volume":"69","author":"Pu\u00e9chal","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.09.010_bib0025","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/art.40802","article-title":"Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: a Randomized Controlled Study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.09.010_bib0026","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","article-title":"Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.09.010_bib0027","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/art.27340","article-title":"Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients","volume":"62","author":"Ribi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0028","unstructured":"A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 10]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02994927"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0029","unstructured":"Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 10]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02433522"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0030","unstructured":"Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 10]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02749292"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0031","unstructured":"Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 3]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03323476"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0032","unstructured":"Daclizumab to Treat Wegener's Granulomatosis - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 3]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00040248"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0033","unstructured":"Retinoids in ANCA Small Vessel Vasculitis: silencing Autoantigens - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 4]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01275274"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0034","unstructured":"Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 4]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01275287"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0035","unstructured":"The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01933724"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0036","unstructured":"Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02117453"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0037","unstructured":"The Clinical Efficacy of DFPP in Patients With AAGN - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02294344"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0038","unstructured":"Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03290456"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0039","unstructured":"Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03482479"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0040","unstructured":"Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03906227"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0041","unstructured":"Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03942887"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0042","unstructured":"Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 6]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03920722"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0043","unstructured":"Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 7]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00004567"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0044","unstructured":"Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA) - Full Text View - ClinicalTrials.gov [Internet]. [cited 2019 Jun 7]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00103792"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0045","unstructured":"JPRN-JMA-IIA00325. Clinical trial of tocilizumab versus cyclophosphamide for microscopic polyangiitis and granulomatosis with polyangiitis. Httpwwwwhointtrialsearchtrial2aspx Trialidjprn-Jma-Iia00325 [Internet]. 2019 Mar 31 [cited 2019 Jun 8]; Available from:https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01901006\/full"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0046","unstructured":"JPRN-UMIN000000708. Efficacy and Safety of mizoribine for MPO-ANCA associated vasculitis; A multicenter randomized controlled trial (Mizoribin for ANCA RPGN Relapse-Prevention study: MARPGN study). Httpwwwwhointsmatteoclascinecaittrialsearchtrial2aspx Trialidjprn-Umin000000708 [Internet]. 2019 Mar 31 [cited 2019 Jun 8]; Available from:https:\/\/www-cochranelibrary-com.smatteo.clas.cineca.it\/central\/doi\/10.1002\/central\/CN-01867263\/full"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0047","unstructured":"JPRN-UMIN000011244. A prospective, open label, randomized, controlled trial of tocilizumab versus cyclophosphamide in patients with microscopic polyangiitis. Httpwwwwhointsmatteoclascinecaittrialsearchtrial2aspx Trialidjprn-Umin000011244 [Internet]. 2019 Mar 31 [cited 2019 Jun 8]; Available from:https:\/\/www-cochranelibrary-com.smatteo.clas.cineca.it\/central\/doi\/10.1002\/central\/CN-01886636\/full"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0048","unstructured":"ChiCTR-TRC-10000990. Mycophenolate Mofetil Versus Cyclophosphamide Versus Leflunomide for Maintenance Therapy in ANCA Associated Systemic Vasculitis with renal involvement in remission. Httpwwwwhointsmatteoclascinecaittrialsearchtrial2aspx Trialidchictr-Trc-10000990 [Internet]. 2019 Mar 31 [cited 2019 Jun 8]; Available from:https:\/\/www-cochranelibrary-com.smatteo.clas.cineca.it\/central\/doi\/10.1002\/central\/CN-01834257\/full"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.09.010_bib0049","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023769","article-title":"Treatment of fatigue with physical activity and behavioural change support in vasculitis: study protocol for an open-label randomised controlled feasibility study","volume":"8","author":"Harper","year":"2018","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.010_bib0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13063-017-1857-z","article-title":"Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial","volume":"18","author":"Gopaluni","year":"2017","journal-title":"Trials"},{"issue":"12","key":"10.1016\/j.semarthrit.2020.09.010_bib0051","article-title":"Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial","volume":"7","author":"Furuta","year":"2017","journal-title":"BMJ Open [Internet]"},{"key":"10.1016\/j.semarthrit.2020.09.010_bib0052","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1745-6215-14-73","article-title":"Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial","volume":"14","author":"Walsh","year":"2013","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.09.010_bib0053","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2020.09.010_bib0054","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.09.010_bib0055","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.09.010_bib0056","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185880","article-title":"Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: a randomised trial","volume":"12","author":"Maritati","year":"2017","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.09.010_bib0057","first-page":"1453","volume":"31","author":"Sanders","year":"2016","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"issue":"19","key":"10.1016\/j.semarthrit.2020.09.010_bib0058","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.010_bib0059","first-page":"206","article-title":"Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis\u2013a clinical randomized controlled trial","volume":"26","author":"Szpirt","year":"2011","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"issue":"1 Suppl 64","key":"10.1016\/j.semarthrit.2020.09.010_bib0060","first-page":"S63","article-title":"Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients","volume":"29","author":"de Menthon","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.09.010_bib0061","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000324364","article-title":"Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis","volume":"33","author":"Han","year":"2011","journal-title":"Am J Nephrol"},{"issue":"21","key":"10.1016\/j.semarthrit.2020.09.010_bib0062","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.09.010_bib0063","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.09.010_bib0064","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.09.010_bib0065","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"issue":"Suppl 4","key":"10.1016\/j.semarthrit.2020.09.010_bib0066","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/2047-783X-14-S4-265","article-title":"Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement","volume":"14","author":"Zycinska","year":"2009","journal-title":"Eur J Med Res"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.09.010_bib0067","first-page":"1307","article-title":"Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement","volume":"23","author":"Hu","year":"2008","journal-title":"Nephrol Dial Transpl Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"issue":"26","key":"10.1016\/j.semarthrit.2020.09.010_bib0068","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.09.010_bib0069","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","article-title":"Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis","volume":"46","author":"Metzler","year":"2007","journal-title":"Rheumatol Oxf Engl"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.09.010_bib0070","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol JASN"},{"issue":"8","key":"10.1016\/j.semarthrit.2020.09.010_bib0071","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.09.010_bib0072","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.010_bib0073","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.010_bib0074","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.10922","article-title":"Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients","volume":"49","author":"Guillevin","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2020.09.010_bib0075","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","article-title":"A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis","volume":"40","author":"Guillevin","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.010_bib0076","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group","volume":"335","author":"Stegeman","year":"1996","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1016\/j.semarthrit.2020.09.010_bib0077","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q","article-title":"Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study","volume":"41","author":"Haubitz","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.09.010_bib0078","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/qjmed\/90.6.401","article-title":"Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis","volume":"90","author":"Adu","year":"1997","journal-title":"QJM Mon J Assoc Physicians"},{"issue":"8717","key":"10.1016\/j.semarthrit.2020.09.010_bib0079","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0140-6736(90)92205-V","article-title":"The TH, van der Hem GK, et\u00a0al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre","volume":"336","author":"Tervaert","year":"1990","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.010_bib0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/ard.2008.097758","article-title":"Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis","volume":"68","author":"Merkel","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.09.010_bib0081","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/03009742.2016.1188980","article-title":"Clinicians\u2019 perspective on key domains in ANCA-associated vasculitis: a Delphi exercise","volume":"46","author":"Milman","year":"2017","journal-title":"Scand J Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.09.010_bib0082","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3899\/jrheum.181073","article-title":"Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: patient Perspective Using the International Classification of Function, Disability, and Health","volume":"46","author":"Milman","year":"2019","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2020.09.010_bib0083","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2017-212713","article-title":"Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire","volume":"77","author":"Robson","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.09.010_bib0084","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3899\/jrheum.161139","article-title":"OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis","volume":"44","author":"Robson","year":"2017","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.09.010_bib0085","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1136\/annrheumdis-2012-201519","article-title":"Near misses of ACR\/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions","volume":"71","author":"Studenic","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.09.010_bib0086","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/art.38248","article-title":"Brief Report: the Value of a Patient Global Assessment of Disease Activity in Granulomatosis With Polyangiitis (Wegener\u2019s)","volume":"66","author":"Tomasson","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.09.010_bib0087","first-page":"137","article-title":"Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"37","author":"Montante","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.09.010_bib0088","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s10067-011-1838-7","article-title":"Estimation of BVAS in patients with microscopic polyangiitis in Japan","volume":"30","author":"Itabashi","year":"2011","journal-title":"Clin Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:04:20Z","timestamp":1758733460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220302638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":88,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0049017220302638"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.09.010","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}